Financial reports
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
13 Nov 20
NT 10-Q
Notice of late quarterly filing
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
8 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
11 Mar 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
Current reports
8-K
Entry into a Material Definitive Agreement
14 Dec 20
8-K
PDL Announces Timeline for Voluntarily Delisting from Nasdaq
8 Dec 20
8-K
PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
13 Nov 20
8-K
Completion of Acquisition or Disposition of Assets
7 Oct 20
8-K
PDL BioPharma Completes Spin-Off of LENSAR
2 Oct 20
8-K
Regulation FD Disclosure
10 Sep 20
8-K
Other Events
10 Sep 20
8-K
PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital
9 Sep 20
8-K
Amendments to Articles of Incorporation or Bylaws
31 Aug 20
8-K
PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties
31 Aug 20
Registration and prospectus
SC TO-I/A
Issuer tender offer statement (amended)
19 Feb 21
POS AM
Prospectus update (post-effective amendment)
2 Feb 21
POS AM
Prospectus update (post-effective amendment)
2 Feb 21
POS AM
Prospectus update (post-effective amendment)
2 Feb 21
POS AM
Prospectus update (post-effective amendment)
2 Feb 21
POS AM
Prospectus update (post-effective amendment)
2 Feb 21
POS AM
Prospectus update (post-effective amendment)
2 Feb 21
POS AM
Prospectus update (post-effective amendment)
2 Feb 21
POS AM
Prospectus update (post-effective amendment)
1 Feb 21
POS AM
Prospectus update (post-effective amendment)
1 Feb 21
Proxies
DEFA14A
Additional proxy soliciting materials
6 Aug 20
DEFA14A
Additional proxy soliciting materials
6 Aug 20
DEF 14A
Definitive proxy
7 Jul 20
PRER14A
Preliminary revised proxy
30 Jun 20
PRER14A
Preliminary revised proxy
5 Jun 20
DEFA14A
Additional proxy soliciting materials
7 May 20
PRE 14A
Preliminary proxy
5 May 20
DEFA14A
Additional proxy soliciting materials
11 Mar 20
DEFA14A
Additional proxy soliciting materials
28 Feb 20
DEFA14A
Additional proxy soliciting materials
15 Jan 20
Other
EFFECT
Notice of effectiveness
4 Feb 21
EFFECT
Notice of effectiveness
4 Feb 21
EFFECT
Notice of effectiveness
4 Feb 21
EFFECT
Notice of effectiveness
4 Feb 21
EFFECT
Notice of effectiveness
4 Feb 21
EFFECT
Notice of effectiveness
4 Feb 21
EFFECT
Notice of effectiveness
4 Feb 21
EFFECT
Notice of effectiveness
2 Feb 21
EFFECT
Notice of effectiveness
2 Feb 21
UPLOAD
Letter from SEC
8 Jul 20
Ownership
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
9 Feb 24
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
10 Feb 23
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
8 Feb 22
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
12 Feb 21
SC 13G/A
BRANDES INVESTMENT PARTNERS, LP
11 Feb 21
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
11 Feb 21
4
Robert J O'Shea
3 Feb 21
SC 13D
Silver Point Capital L.P.
11 Jan 21
3
Initial statement of insider ownership
11 Jan 21
SC 13G/A
Park West Asset Management LLC
11 Jan 21